Uniunea Europeană - letonă - EMA (European Medicines Agency)

bayer animal health gmbh  - pradofloksacīns - antibakteriālas līdzekļi sistēmiskai lietošanai, fluorhinoloniem - dogs; cats - dogstreatment:brūču infekcijām, ko izraisa uzņēmīgi celmiem staphylococcus intermedius grupas (tostarp s. pseudintermedius);virspusēja un dziļa pyoderma, ko izraisa uzņēmīgi celmiem staphylococcus intermedius grupas (tostarp s. pseudintermedius);akūta urīna-trakta infekcijām, ko izraisa uzņēmīgi celmu escherichia coli un staphylococcus intermedius grupas (tostarp s. pseudintermedius);kā adjunctive attieksmi pret mehāniskiem vai periodontīta ķirurģiska terapija, ārstējot smagas infekcijas gingiva un periodonta audos, ko izraisa uzņēmīgi celmu anaerobi organismi, piemēram porphyromonas spp. un prevotella spp. catstreatment akūtas infekcijas augšējo elpošanas ceļu, ko izraisa uzņēmīgi celmu pasteurella multocida, escherichia coli un staphylococcus intermedius grupas (tostarp s. pseudintermedijs).

Uniunea Europeană - letonă - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - gamitromicīns - antibakteriālie līdzekļi sistēmiskai lietošanai - cattle; pigs; sheep - cattletreatment un metaphylaxis liellopu elpošanas ceļu slimības (brd), kas saistīti ar mannheimia haemolytica, pasteurella multocida un histophilus somni. slimības klātbūtne ganāmpulkā ir jānosaka pirms metapilkta lietošanas. pigstreatment cūku elpošanas ceļu slimības (srd), kas saistīti ar actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis un bordetella bronchiseptica. sheeptreatment infekcijas pododermatitis (pamatnes puve), kas saistīts ar bīstamu dichelobacter nodosus un fusobacterium necrophorum nepieciešama sistēmiska ārstēšana.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

intervet international bv - tildipirozīns - antiinfectives līdzekļi sistēmiskai lietošanai - pigs; cattle - 40 mg/ml šķīdums injekcijām pigstreatment un metaphylaxis cūku elpošanas ceļu slimības (srd), kas saistīti ar actinobacillus pleuropneumoniae, pasteurella multocida, bordetella bronchiseptica un haemophilus parasuis jutīgas pret tildipirosin. slimības klātbūtne ganāmpulkā jāapstiprina pirms metafilakses ieviešanas. 180 mg/ml šķīdums injekcijām cattlefor ārstēšanai un profilaksei liellopu elpošanas ceļu slimības (brd), kas saistīti ar mannheimia haemolytica, pasteurella multocida un histophilus somni jutīgas pret tildipirosin. slimības klātbūtne ganāmpulkā jāapstiprina pirms profilaktiskas ārstēšanas.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

roche registration gmbh - saquinavir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - invirase indicēts hiv-1 inficētiem pieaugušiem pacientiem. invirase drīkst lietot tikai kopā ar ritonavīru un citiem pretretrovīrusu līdzekļiem.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

"anpharm" przedsiębiorstwo farmaceutyczne s.a. - ivabradine - angina pectoris; heart failure - other cardiac preparations - simptomātiska ārstēšana hroniska stabila stenokardija pectorisivabradine ir norādīts simptomātiska ārstēšana hroniska stabila stenokardija, koronāro artēriju slimība pieaugušajiem ar normālu sinusa ritmu un sirdsdarbības ātrumu ≥ 70 bpm. ivabradine ir norādīts:pieaugušajiem nespēj paciest vai ar contra-norāde izmantot beta-blockersor kombinācijā ar beta-blokatori pacientiem nepietiekami kontrolēta ar optimālu devu betablocker. hroniskas sirds failureivabradine ir norādīts hroniskas sirds mazspējas nyha ii-iv klase ar sistolisku disfunkciju, pacientiem ar sinusa ritmu un kuru sirdis līmenis ir ≥ 75 bpm, kombinācijā ar standarta terapiju, ieskaitot beta-blokatoru terapiju, vai, ja beta-blokatoru terapija ir kontrindicēta vai nav pieļaujama.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

merck sharp & dohme b.v. - fosaprepitants - vomiting; cancer - pretvemšanas un antinauseants, - profilakses, slikta dūša un vemšana, kas saistīta ar augsti un vidēji emetogenic vēža ķīmijterapija pieaugušajiem un pediatrijas pacienti vecumā no 6 mēneši un vecāki. ivemend 150 mg ir sniegta kā daļa no terapijas kombinācija.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

novartis europharm limited - ruksolitinibs (fosfāts) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiski līdzekļi - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi ir norādīts ārstēšanai pieaugušiem pacientiem ar polycythaemia vera, kas ir izturīgas pret vai nepanes hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin, metformīns - cukura diabēts, 2. tips - cukura diabēts - Ārstēšana pieaugušiem pacientiem ar 2. tipa cukura diabētu:jentadueto ir norādīts kā palīglīdzekli, lai diētu un vingrinājumiem, lai uzlabotu glycaemic kontroles pieaugušo pacientu nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns viens pats, vai arī tiem, kas jau tiek ārstēti ar kombināciju linagliptin un metformīns. jentadueto ir norādīts kombinācijā ar sulfonilurīnvielas pamata, (es. trīskāršās kombinācijas terapija), kā palīglīdzekli, lai diētu un vingrošanu pieaugušo pacientu nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

inceptua ab - ocriplasmin - tīklenes slimības - oftalmoloģiskie līdzekļi - jetrea ir indicēts pieaugušajiem vitreomakulārās trakcijas (vmt) ārstēšanai, arī tad, ja tas saistīts ar makulas caurumu, kura diametrs ir mazāks vai vienāds ar 400 mikroniem.

Uniunea Europeană - letonă - EMA (European Medicines Agency)

merck sharp & dohme b.v. - pembrolizumabs - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; endometrial neoplasms - antineoplastiski līdzekļi - melanomakeytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with stage iib, iic, or with stage iii melanoma and lymph node involvement who have undergone complete resection. non small cell lung carcinoma (nsclc)keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum based chemotherapy (for selection criteria, see section 5. keytruda as monotherapy is indicated for the first line treatment of metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 50% tumour proportion score (tps) with no egfr or alk positive tumour mutations. keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non squamous non small cell lung carcinoma in adults whose tumours have no egfr or alk positive mutations. keytruda, in combination with carboplatin and either paclitaxel or nab paclitaxel, is indicated for the first line treatment of metastatic squamous non small cell lung carcinoma in adults. keytruda  as monotherapy is indicated for the treatment of locally advanced or metastatic non small cell lung carcinoma in adults whose tumours express pd l1 with a ≥ 1% tps and who have received at least one prior chemotherapy regimen. pacientiem ar egfr vai bĀziskĀ pozitīvas mutācijas audzēja arī būtu saņēmuši mērķtiecīgu terapiju, pirms saņem keytruda. classical hodgkin lymphoma (chl)keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical hodgkin lymphoma who have failed autologous stem cell transplant (asct) or following at least two prior therapies when asct is not a treatment option. urothelial carcinomakeytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum containing chemotherapy. keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin containing chemotherapy and whose tumours express pd l1 with a combined positive score (cps) ≥ 10. head and neck squamous cell carcinoma (hnscc)keytruda, as monotherapy or in combination with platinum and 5 fluorouracil (5 fu) chemotherapy, is indicated for the first line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a cps ≥ 1. keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express pd l1 with a ≥ 50% tps and progressing on or after platinum containing chemotherapy. renal cell carcinoma (rcc)keytruda, in combination with axitinib, is indicated for the first line treatment of advanced renal cell carcinoma in adults. keytruda  as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, please see section 5. microsatellite instability high (msi-h) or mismatch repair deficient (dmmr) cancerscolorectal cancer (crc)keytruda as monotherapy is indicated for theadults with msi-h or dmmr colorectal cancer in the following settings:first line treatment of metastatic microsatellite instability high (msi h) or mismatch repair deficient (dmmr) colorectal cancer in adults;treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy.  non-colorectal cancerskeytruda as monotherapy is indicated for the treatment of the following msi h or dmmr tumours in adults with:advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation;unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. oesophageal carcinomakeytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus or her-2 negative gastroesophageal junction adenocarcinoma, in adults whose tumours express pd l1 with a cps ≥ 10. triple negative breast cancer (tnbc)keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early stage triple negative breast cancer at high risk of recurrence. keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express pd l1 with a cps ≥ 10 and who have not received prior chemotherapy for metastatic disease. endometrial carcinoma (ec)keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. cervical cancerkeytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express pd l1 with a cps ≥ 1. gastric or gastro-oesophageal junction (gej) adenocarcinomakeytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic her2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express pd-l1 with a cps ≥ 1.